The Medical Letter on Drugs and Therapeutics
Suvorexant (Belsomra) for Insomnia
March 2, 2015 (Issue: 1463)The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
- Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57.
- RA España and TE Scammell. Sleep neurobiology from a clinical perspective. Sleep 2011; 34:845.
- WJ Herring et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 2014. Oct 23 (epub).
- WJ Herring et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012; 79:2265.
- D Michelson et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13:461.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.